17,261 trials
Ovarian Carcinoma · Endometrial Carcinoma · Cervical Carcinoma
Primary: Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 30.4; 36.4; 24.0; 33.3…
Diffuse Large Cell Lymphoma · Lymphoma
Primary: Number of Participants With a 2-Year Progression-Free Survival (PFS) — 6; 8; 8; 5 Participants
Blastic Phase · Childhood Acute Promyelocytic Leukemia With PML-RARA · Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level — 0; 0; 5; 1 Participants
Osteoarthritis · OA Knee Pain · Arthritis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 168; 8 Participants
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent…
Stress Urinary Incontinence
Primary: The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary — 81 percent reduction
Sphingomyelin Lipidosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 9; 7; 20 Participants
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)] — -1.33; -1.15 Percentage point of HbA1c — p=0.0818
Ulcerative Colitis
Primary: Clinical Remission — 5; 2; 9; 4 Participants — p=0.1806
Advanced Cancers · Hematologic Disorder · Solid Tumors
Primary: Number of Participants Who Completed the Dyspnea Numeric Rating Scale — 18; 17 Participants
NAFLD · Diabetes Mellitus, Type 2 · Hypertriglyceridemia
Primary: Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point — -16; -36; -53; -47 percent change — p=0.0343
B Acute Lymphoblastic Leukemia · Recurrent Childhood Acute Lymphoblastic Leukemia · Refractory Childhood Acute Lymphoblastic Leukemia
Primary: Number of Patients With Grade 3-5 Toxicities Occurring Within the Dose Limiting Toxicity (DLT) Period of AUTO3 Infusion — 4; 4; 6 Participants
Hereditary Angioedema Types I and II
Primary: Modeled C1-esterase Inhibitor Functional Activity Trough Level — 30.3; 45.9; 80.6 percent functional activity
Sickle Cell Anemia · Thalassemia
Primary: Number of Occurrences of Painful Sickle Cell Crises — 4.5; 10.8 Crisis — p=0.076
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants